Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study checks how well venetoclax works for AML patients

NCT ID NCT05215639

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well the drug Venetoclax works for adults with acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 120 patients in Switzerland and Austria took Venetoclax pills daily as part of their normal care. Researchers tracked survival and remission rates over 24 months to see how effective the treatment is in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Venetoclax (a targeted cancer drug taken as a pill)
What this could lead to
If successful, this study could confirm that Venetoclax is a good treatment option for AML patients who cannot tolerate intensive chemotherapy.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only included patients in Switzerland and Austria, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

120 people

The number who actually took part.

Started

Dec 2021

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with acute myeloid leukemia (AML) treated with Venetoclax per approved local label in Switzerland \& Austria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly-diagnosed AML and eligible to receive venetoclax as per local label. * Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study. Exclusion Criteria: \- Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia

Contacts and locations

Locations

  • Duplicate_Universitätsspital Basel /ID# 256509

    Basel, Canton of Basel-City, 4031, Switzerland

  • EOC Ospedale Regionale di Bellinzona e Valli /ID# 240663

    Bellinzona, Canton Ticino, 6500, Switzerland

  • Hanusch Krankenhaus /ID# 247282

    Vienna, 1140, Austria

  • Hirslanden Klinik /ID# 239239

    Zurich, Canton of Zurich, 8032, Switzerland

  • Hôpital de Nyon /ID# 240720

    Nyon, 1260, Switzerland

  • Hôpital du Chablais, Rennaz /ID# 241895

    Rennaz, Canton of Vaud, 1847, Switzerland

  • Inselspital, Universitaetsspital Bern /ID# 239241

    Bern, 3010, Switzerland

  • KSW Kantonsspital Winterthur /ID# 239852

    Winterthur, Canton of Zurich, 8400, Switzerland

  • Kantonsspital Aarau AG /ID# 251598

    Aarau, Canton of Aargau, 5001, Switzerland

  • Kantonsspital Baden /ID# 241896

    Baden, Canton of Aargau, 5404, Switzerland

  • Kantonsspital St. Gallen /ID# 239233

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

  • Klinik Ottakring /ID# 247285

    Vienna, State of Vienna, 1160, Austria

  • Klinikum Klagenfurt am Wörthersee /ID# 247304

    Klagenfurt, Carinthia, 9020, Austria

  • Krankenhaus der Barmherzigen Brueder Graz /ID# 254121

    Graz, Styria, 8020, Austria

  • Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 254174

    Leoben, Styria, 8700, Austria

  • Luzerner Kantonsspital /ID# 239242

    Lucerne, Canton of Lucerne, 6000, Switzerland

  • Ordensklinikum Linz GmbH Elisabethinen /ID# 247284

    Linz, Upper Austria, 4010, Austria

  • Spitalzentrum Oberwallis /ID# 241897

    Brig, Valais, 3900, Switzerland

  • Universitaetsklinikum St. Poelten /ID# 247283

    Sankt Pölten, Lower Austria, 3100, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.